|
Aug 8
|
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis
|
|
Aug 6
|
Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffirms Growth Momentum
|
|
Jul 27
|
Cosmo Pharmaceuticals First Half 2025 Earnings: €0.13 loss per share (vs €4.42 profit in 1H 2024)
|
|
Jul 23
|
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology
|
|
Jul 17
|
Cosmo Announces Launch of Winlevi(R) for Treatment of Acne in Singapore and Malaysia
|
|
Jul 16
|
Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact Commitment, and Climate Action Pledge
|
|
Feb 12
|
Cosmo to Host Investor Day on April 9, 2025
|
|
Feb 11
|
Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio
|
|
Jul 24
|
Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance
|
|
Jun 18
|
Cosmo's Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China
|
|
May 31
|
Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024
|
|
Dec 18
|
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues Pushing Shares 37% Higher
|
|
Dec 13
|
Medtronic (MDT) Expands AI-Driven Care With New Partnership
|
|
Dec 11
|
Medtronic expands AI endoscopy partnership with Cosmo
|
|
Dec 11
|
Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care
|